Beren Therapeutics

Coming – October 20

Building the 100-Year Biotech

Date and Time

October 20

–

4:00 PM ET / 1:00 PM PT

Details will be shared with confirmed attendees

About this Event

Why the traditional biotechnology model may need to change

Before founding Beren, Jason Camm spent years evaluating biotechnology companies from the investor’s side of the table. Now he’s applying those lessons to a different question: What would you build differently if your goal wasn’t an exit, but a biotechnology company designed to endure for generations?

Biotechnology has produced extraordinary scientific breakthroughs, yet relatively few biotech companies become enduring, fully integrated businesses. Too often, companies are built around a molecule, a clinical milestone, or an eventual acquisition rather than around the idea of creating a lasting enterprise.

Jason Camm, Founder and CEO of Beren Therapeutics, believes there is another way.

Join us for a Fireside Chat exploring Beren’s ambitious 100-year vision and what it takes to build a biotechnology company designed not simply to discover new therapies, but to develop, commercialize, and support them for generations.

We’ll discuss why biotech companies often underinvest in commercialization, the advantages and challenges of building an integrated organization, how long-term thinking changes capital allocation, and why remaining independent can create opportunities for both patients and shareholders.

We’ll also explore Beren’s first program, adrabetadex, an investigational treatment for infantile-onset Niemann-Pick disease type C currently under FDA Priority Review.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.